ENTITY
Biocytogen Pharmaceuticals (Beijing)

Biocytogen Pharmaceuticals (Beijing) (2315 HK)

32
Analysis
Health Care • China
Biocytogen Pharmaceuticals Beijing Co., Ltd. operates as a biopharmaceutical and revenue generating pre clinical research services company. The Company produces mmunoglobulins, monoclonal antibodies, recombinant humanized antibodies, and others. Biocytogen Pharmaceuticals Beijing provides drug development, therapeutic antibody discovery and development, and other services.
more
bullish•GQG Partners
•17 Oct 2021 10:27

ECM Weekly (17th October 2021) - SG Lottery, GQG, Judo Bank, Vulcan Steel, Biocytogen, Kakao Pay

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.

Logo
542 Views
Share
•13 Oct 2021 10:33

Biocytogen (百億赛图) Pre-IPO: From Animal CRO to Biotech

We look at Biocytogen's main business line of animal CRO (gene-edited mice) and also its two core assets YH003 and YH001.

Logo
388 Views
Share
x